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Abstract
Mutations in TMEM230 have recently been associated to Parkinson’s disease (PD). To further 
understand the role of this gene in the Caucasian population, we interrogated our large repository 
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of next generation sequencing data from unrelated PD cases and controls, as well as multiplex 
families with autosomal dominant PD. We identified 2 heterozygous missense variants in 2 
unrelated PD cases and not in our control database (p.Y106H and p.I162V), and a heterozygous 
missense variant in 2 PD cases from the same family (p.A163T). However, data presented herein is 
not sufficient to support the role of any of these variants in PD pathology. A series of unified 
sequence kernel association tests also failed to show a cumulative effect of rare variation in this 
gene on the risk of PD in the general Caucasian population. Further evaluation of genetic data 
from different populations is needed to understand the genetic role of TMEM230 in PD etiology.
Keywords
TMEM230; Parkinson’s disease; IPDGC; Rotterdam Study Exome Sequencing; Database; SKAT-
O; Mutation screening
1. Introduction
In a recent publication, Deng et al. showed genetic evidence linking a mutation in 
transmembrane protein 230 (TMEM230) to autosomal dominant Parkinson’s disease (PD) in 
a large family from North America (Deng et al., 2016). Identification of an additional 
mutation in 7 small Chinese families supports their results and suggests that mutations in 
this gene may be a relatively common cause of PD in this population. They also showed that 
TMEM230 encodes a transmembrane protein of synaptic vesicles in neurons and that 
disease-linked mutations impair synaptic vesicle trafficking. Presence of TMEM230 in 
alpha-synuclein-positive Lewy bodies and Lewy neurites in midbrain and neocortex sections 
from sporadic PD cases gave supporting evidence for a role of this gene in PD pathology 
(Deng et al., 2016).
In an effort to understand the role of TMEM230 mutations in the general Caucasian 
population, the authors also screened a larger cohort of 433 familial and 399 sporadic PD 
cases. This led to the identification of 2 additional variants in 2 PD cases from North 
America (Deng et al., 2016). Because these variants were identified in a single PD patient 
each, their pathogenicity—and consequently the role of mutations inTMEM230 in this 
population—remains to be further evaluated.
To further investigate the putative pathogenicity of TMEM230 mutations in the Caucasian 
population, we interrogated our large repository of next-generation sequencing data from 
unrelated PD cases and controls, as well as multiplex families with autosomal dominant PD.
2. Subjects and methods
2.1. IPDGC and Rotterdam Study Exome Sequencing Database (RSX1) cohorts
To establish the role of TMEM230 in the general Caucasian population, we mined our large 
repository of whole exome sequencing (WES) data consisting of 1450 PD cases and 535 
controls from the International Parkinson’s Disease Consortium (IPDGC), and 1732 controls 
from the RSX1 (Hofman et al., 2013, 2015; Ikram et al., 2011). After genotype and variant 
quality control (Supplementary Methods), we were left with a total of 61 variants spanning 
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TMEM230 of which only 10 had a direct impact on the coding sequence of this gene. Only 
2 of these variants were present in PD cases only: NM_001009923: c.T316C: p.Y106H and 
NM_001009923: c.A484G: p.I162V (Table 1).
After a more extensive quality control procedure that included genotype, variant, and 
individual filtering, this data set was also used to perform a series of unified sequence kernel 
association tests (SKAT-O) aiming to understand the cumulative impact of rare variation 
(minor allele frequency [MAF] ≤ 0.01) in TMEM230 on the risk of PD (Lee et al., 2012). 
For this analysis, raw combined annotation dependent depletion scores (http://
cadd.gs.washington.edu/) (Kircher et al., 2014) were used as custom weights for each 
variant, whereas gender, mean sequencing depth, and the first 20 components derived from 
multidimensional scale analysis were used as covariates (Supplementary Methods).
2.2. Multiplex families with autosomal dominant PD
In an effort to replicate the main finding described by Deng et al., we also mined WES and 
whole genome sequencing data from 29 multiplex families with autosomal dominant PD 
originally from France, Spain, Portugal, the Netherlands, and the UK (Supplementary Table 
S1). For each of these families, data on at least 2 PD cases were available. In total, data from 
86 PD cases and 10 controls were analyzed. For details on the quality control procedures 
applied see the Supplementary Methods.
3. Results and discussion
To investigate the putative pathogenicity of TMEM230 mutations in the general Caucasian 
population, we interrogated our large repository of WES data from unrelated PD cases and 
controls (1450 and 2267, respectively) from the IPDGC and the Rotterdam Study RSX1 
(Hofman et al., 2013, 2015; Ikram et al., 2011). This analysis failed to identify any of the 
pathogenic mutations described by Deng et al. although this locus was sequenced at an 
average depth of ~30×, suggesting that these variants are very rare. Further investigation of 
our WES data identified 2 rare heterozygous missense variants (NM_001009923: c.T316C: 
p.Y106H and NM_001009923: c.A484G: p.I162V) present in 2 North American PD cases 
and not present in any of the control samples investigated (p = 0.37 and 0.38 after Fisher’s 
exact test; Table 1). Both carriers suffer of bradykinesia, activation tremor, resting tremor, 
rigidity and were classified as nonfamilial. The variants identified had 1 and 2 alleles, 
respectively, in European (non-Finnish) ExAC population (MAF = 0.00001501 and 
0.00002997) and were predicted to be pathogenic as per phred combined annotation 
dependent depletion scores of 24 and 22.2(Amendola et al., 2015; Kircher et al., 2014), 
affecting amino acid positions highly conserved across species (Supplementary Fig. S1). 
Although the frequency of these variants is higher among the PD exomes investigated than 
that in European samples from ExAC database (p = 0.075466 and 0.109979 after Fisher 
exact test) we think that the data presented here are not sufficient to definitively support their 
role in the etiology of PD and that further evaluation in larger cohorts of PD patients is 
needed.
In an effort to understand the cumulative effect of rare variants (MAF ≤ 0.01) in this gene on 
the risk of PD, a set of SKAT-O tests were performed in this same data set, considering 
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different levels of variant functionality (Supplementary Methods). None of these tests 
derived significant results (lowest p = 0.34 when considering coding variants only, 
Supplementary Table S2).
Because the main finding described by Deng et al. derives from the analysis of a large 
family with autosomal dominant PD, we also investigated whether mutations in TMEM230 
cosegregated with this disease in WES/whole genome sequencing data from 29 multiplex 
dominant families from different European populations. In a large PD family we previously 
reported (Kindred A) (Nicholl et al., 2002), we found a rare variant in 2 cousins. This variant 
(rs374122606; NM_001009923:c.G487A:p.A163T) has only 2 alleles in European 
populations from ExAC (MAF = 0.00001647) and was predicted damaging (Table 1). 
However, linkage analysis suggested that this region is unlikely to be harboring the gene that 
causes PD in this family (Supplementary Fig. S2). A polymerase chain reaction followed by 
Sanger sequencing (primers available upon request) confirmed that the identified variant 
does not segregate with PD in this family.
In summary, our results do not support a genetic role of TMEM230 both in the general 
Caucasian population and a set of families with autosomal dominant PD. Although we 
identified 2 variants in 2 PD cases that are not present in our control database, lack of family 
history, as well as the presence of the identified variants in ExAC database, makes it difficult 
to understand whether they represent pathogenic mutations or very rare benign events. We 
also identified a pathogenic variant in 2 PD cases from the same family. However, linkage 
data suggest that this variant is not the cause of PD in this family. A series of SKAT-O tests 
also failed to show a cumulative effect of rare variation in this gene on the risk of PD in the 
general Caucasian population. Further evaluation of whole exome/genome sequencing data 
from the PD research community is needed to clarify the role of this gene in the general 
population.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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